Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-03-27 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
湖南启元律师事务所关于圣湘生物科技股份有限公司2025年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the convening, attendance, voting procedures, and results of a specific shareholders' meeting (the 2025 second extraordinary general meeting) of 圣湘生物科技股份有限公司. It details the meeting notice, voting methods, attendance verification, and voting results, and concludes on the legality and validity of the meeting and its resolutions. This document is not the meeting materials themselves, nor is it a report of voting results or a proxy solicitation. It is a legal opinion related to the shareholders' meeting. Given the content and nature, it best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the voting procedures and results' legality and validity. The document length is under 5,000 characters, but it contains substantive legal opinion on the meeting and voting results, not just an announcement of a report publication. Therefore, the classification is DVA with high confidence.
2025-03-27 Chinese
圣湘生物科技股份有限公司关于2021年限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期归属结果公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the results of the vesting of restricted stock under a 2021 stock incentive plan. It details the number of shares vested, the decision-making process, the verification by the board and supervisory committee, legal opinions, and the completion of share registration. It also includes an audit report on the capital verification related to the stock incentive plan. The document is not a full annual or interim financial report, nor is it a proxy solicitation or remuneration report. It is a formal announcement about the stock incentive plan vesting results and related share registration, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Director's Dealing or Share Issue/Capital Change since it is about restricted stock vesting results and registration confirmation rather than new share issuance or insider trading. The document length is substantial and contains detailed information, but it is primarily an announcement of vesting results and related confirmations rather than a financial report or presentation.
2025-03-27 Chinese
圣湘生物科技股份有限公司2025年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's 2025 second extraordinary general meeting of shareholders. It details the meeting date, attendance, voting results, and legal compliance statements. There is no financial data or report content, only the voting results and procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2025-03-27 Chinese
圣湘生物科技股份有限公司2025年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2025 Second Extraordinary General Meeting (EGM) Meeting Materials" of 圣湘生物科技股份有限公司. It contains detailed meeting instructions, agenda, and a specific proposal regarding the acquisition and capital increase related to 深圳市真迈生物科技有限公司. The content includes meeting procedures, voting rules, and detailed information about the investment proposal to be discussed and voted on at the EGM. There is no indication that this is a full annual or interim report, earnings release, or other financial report. Instead, it is clearly the meeting materials provided to shareholders for the EGM. According to the filing definitions, presentations and materials shared during a general meeting (including extraordinary meetings) fall under AGM Information (AGM-R). Although this is an extraordinary meeting, the category AGM-R is the closest and most appropriate classification for meeting materials. The document length (7178 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement or notice. Therefore, the correct classification is AGM Information (AGM-R).
2025-03-19 Chinese
圣湘生物科技股份有限公司关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 second extraordinary general meeting of shareholders (临时股东大会) of 圣湘生物科技股份有限公司. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements, audit results, or detailed financial performance data. It is an announcement related to a shareholders meeting rather than the meeting materials or results themselves. The document length is 3225 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-03-11 Chinese
圣湘生物科技股份有限公司关于作废2021年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company regarding the cancellation of certain unvested restricted stock under the 2021 restricted stock incentive plan. It details board and supervisory meetings, legal opinions, and compliance with relevant laws and regulations. The content focuses on corporate governance and stock incentive plan adjustments rather than financial results or earnings. It is not a full financial report, earnings release, or audit report. It is also not a proxy solicitation or voting results announcement. The document is a regulatory announcement about management and board decisions related to stock incentives, fitting best under Regulatory Filings (RNS) as it does not fit more specific categories like MANG (management changes) or SHA (share issue). The document length is under 5,000 characters, but it contains substantive disclosure rather than just a report publication notice, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2025-03-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.